# A Study of AK119 (Anti-CD73) in Combination With AK104 in Subjects With Advanced Solid Tumors

> **NCT04572152** · PHASE1 · COMPLETED · sponsor: **Akeso** · enrollment: 23 (actual)

## Conditions studied

- Advanced or Metastatic Solid Tumors

## Interventions

- **BIOLOGICAL:** AK119
- **BIOLOGICAL:** AK104

## Key facts

- **NCT ID:** NCT04572152
- **Lead sponsor:** Akeso
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-07
- **Primary completion:** 2023-05-02
- **Final completion:** 2023-08-31
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2025-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04572152

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04572152, "A Study of AK119 (Anti-CD73) in Combination With AK104 in Subjects With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04572152. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*